A Phase 4 interventional study of Lisdexamfetamine dimesylate in Attention Deficit Hyperactivity Disorder (ADHD), sponsored by Shire. Completed at 35 sites in 10 countries. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2021-06-10.
Sponsored by Shire (part of Takeda) · Phase 4, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity — 1 open to participants now, 1 under way, none of them phase 3. lisdexamfetamine · Attention Deficit Disorder with Hyperactivity.
Among the 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity, this one is the 7th largest by enrollment, is one of 3 that started in 2011, is one of 23 in phase 4, and was the 30th registered.
1,817 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 295 are open to participants now.
Browse Attention Deficit Disorder with Hyperactivity studies →1 of the 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity is open now, in 1 country. Recruiting first, the newest first:
Medical University of Lodz · Sites in Poland
Ages 8 yrs–198 mo
By country, each count listing its studies:
lisdexamfetamine: first FDA approval 2007 (VYVANSE). What it is approved for, and how studies give it, is on its page →
Of the 201 Attention Deficit Disorder with Hyperactivity studies recruiting now, 27 (13%) set no upper age limit and 169 (84%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.
This study: 6 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
51 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 6 · Phase 3 15 · Phase 4 23
First in 2004; this study’s year is marked. 3 started in 2011.
This study's enrollment of 314 is above the median of 71 across 1,437 interventional studies indexed under Attention Deficit Disorder with Hyperactivity.
Median enrollment 48 across the 51 interventional studies. Of the 49 that completed or were terminated, 37 (76%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 51 have an industry lead sponsor. The 10 most frequent:
This study is registered under Shire, one of the names counted as Takeda. Under that name alone:
Shire is the lead sponsor of 351 studies on the registry; 2 are open to participants now.
Of its 48 completed or terminated interventional studies of FDA-regulated products, 48 (100%) have results posted.
57 studies in Attention Deficit Disorder with Hyperactivity by Takeda: none open now, none under way, none of them phase 3. Of 55 finished, 37 (67%) have results posted.
Among the 57 studies in Attention Deficit Disorder with Hyperactivity by Takeda, this one is the 17th largest by enrollment of the 53 interventional ones that give a count, is one of 4 that started in 2011, is one of 8 in phase 4, and was the 39th registered.
Takeda’s Attention Deficit Disorder with Hyperactivity studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Takeda’s 57 in Attention Deficit Disorder with Hyperactivity:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
While the Lisdexamfetamine Dimesylate (SPD489) clinical program has studied the efficacy, safety, and tolerability of SPD489 in treating core symptoms of ADHD in children and adolescents aged 6-17 years and adults aged 18-55 years, the majority of these studies have been of short duration - up to 8 weeks.
A number of long-term studies have been undertaken (up to 1 year) and these have confirmed the safety and ongoing efficacy in this patient population.
In order to run a study with investigational medication within Poland the study changed to a Phase 3 rather than a Phase 4 study in that country. Please note that the study number remains as SPD489-404.
Study SPD489-404 has been designed to further evaluate the long-term effects of SPD489 in children and adolescents over a 2-year treatment period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For subjects who participated in another SPD489 study (SPD489-317, SPD489-325, or SPD489 326):
For subjects who have not participated in another SPD489 study:
For all subjects:
Exclusion Criteria:
For subjects who participated in another SPD489 study (SPD489-317, SPD489-325, or SPD489 326):
For all subjects:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Lisdexamfetamine dimesylate
Optimized dose of either 30, 50 or 70 mg capsule administered once daily for 2 years
Also known as: Vyvanse, SPD489, LDX
Number of Participants With All Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs
An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. It included both serious and non-serious adverse event. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs were defined as treatment-emergent if they started or worsened during the period between the day of a participant's first dose of investigational product in this study and the 3 days following cessation of treatment.
Time frame: Baseline up to 3 days after the last dose of study treatment (up to 2 years)
Change From Baseline in Pulse Rate at Last On-treatment Assessment (LOTA)
Time frame: Baseline (Week 0), LOTA (Week 104)
Change From Baseline in Sitting Diastolic Blood Pressure (DBP) at Last On-treatment Assessment (LOTA)
Time frame: Baseline (Week 0), LOTA (Week 104)
Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Last On-treatment Assessment (LOTA)
Time frame: Baseline (Week 0), LOTA (Week 104)
Change From Baseline in Body Weight at Last On-treatment Assessment (LOTA)
Time frame: Baseline (Week 0), LOTA (Week 104)
Change From Baseline in Height at Last On-treatment Assessment (LOTA)
Time frame: Baseline (Week 0), LOTA (Week 104)
Change From Baseline in Body Mass Index (BMI) at Last On-treatment Assessment (LOTA)
BMI was calculated as (weight \[kilogram\] per height \[square meter\]).
Time frame: Baseline (Week 0), LOTA (Week 104)
Change From Baseline in Heart Rate at Last On-treatment Assessment (LOTA)
Time frame: Baseline (Week 0), LOTA (Week 104)
Change From Baseline in QT Interval at Last On-treatment Assessment (LOTA)
Time frame: Baseline (Week 0), LOTA (Week 104)
Change From Baseline in QT Interval Corrected Using Fridericia's Formula (QTcF) at Last On-treatment Assessment (LOTA)
Time frame: Baseline (Week 0), LOTA (Week 104)
Change From Baseline in Brief Psychiatric Rating Scale for Children (BPRSC) Total Scores at Last On-treatment Assessment (LOTA)
The BPRS-C that was designed to provide a characterization of the child and adolescent psychopathology, was used to monitor participant's safety. The BPRS-C assessed 7 independent factors (3 items each), for a total of 21 items that represented behavioural disorders, depression, thinking disturbance, psychomotor excitation, withdrawal retardation, anxiety, and organicity. Each item was rated using a 7-point scale including 0 (not present), 1 (very mild), 2 (mild), 3 (moderate), 4 (moderately severe), 5 (severe), and 6 (extremely severe). Total score is the sum of each item score; range from 0 to 126. Higher score indicated worse psychology.
Time frame: Baseline (Week 0), LOTA (Week 104)
Change From Baseline in the Attention-Deficit/Hyperactivity Disorder Rating Scale-IV (ADHD-RS-IV) Total Score at Last On-treatment Assessment (LOTA)
ADHD-RS-IV consisted of 18 items designed to reflect current symptomatology of ADHD based on Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition - Text Revision (DSM-IV-TR) criteria, completed by the Investigator. Each item was scored from a range of 0 (reflecting no symptoms) to 3 (reflecting severe symptoms) with total scores ranging from 0-54. The 18 items were grouped into 2 sub-scales: hyperactivity/impulsivity (even number items 2-18 with score range of 0 to 27) and inattention (odd number items 1-17 with score range of 0 to 27). Higher scores depicted worse symptoms.
Time frame: Baseline (Week 0), LOTA (Week 104)
Number of Participants With Clinical Global Impression-Global Improvement (CGI-I) at Last On-treatment Assessment (LOTA)
The Clinical Global Impressions (CGI) Scale permits a global evaluation of the participants' severity and improvement over time. This assessment will help guide the clinician on dosing adjustments. The CGI has been used extensively in clinical studies of ADHD. CGI-I was a 7-point scale ranging from 1 (very much improved) to 7 (very much worse), evaluated by the Investigator.
Time frame: LOTA (Week 104)
Number of Participants With Clinical Global Impression-Severity of Illness (CGI-S) at Last On-treatment Assessment (LOTA)
The Clinical Global Impressions (CGI) Scale permits a global evaluation of the participants' severity and improvement over time. This assessment will help guide the clinician on dosing adjustments. The CGI has been used extensively in clinical studies of ADHD. CGI-S was a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill participants), evaluated by the Investigator.
Time frame: LOTA (Week 104)
This study enrolled participants from 3 antecedent studies (SPD489-317 \[NCT01106430\], SPD489-325 \[NCT00763971\], and SPD489-326 \[NCT00784654\]), or directly enrolled.
| Milestone | Lisdexamfetamine Dimesylate |
|---|---|
| Started | 314 |
| Completed | 191 |
| Not completed | 123 |
| Withdrew: Protocol violation | 4 |
| Withdrew: Adverse event | 39 |
| Withdrew: Lack of efficacy | 5 |
| Withdrew: Withdrawal by subject | 41 |
| Withdrew: Lost to follow-up | 5 |
| Withdrew: Other | 29 |
An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. It included both serious and non-serious adverse event. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs were defined as treatment-emergent if they started or worsened during the period between the day of a participant's first dose of investigational product in this study and the 3 days following cessation of treatment.
| participants | Lisdexamfetamine Dimesylate |
|---|---|
| Any TEAE | 282 |
| Serious TEAE | 28 |
| beats per minute | Lisdexamfetamine Dimesylate |
|---|---|
| Change From Baseline in Pulse Rate at Last On-treatment Assessment (LOTA) | 7 ± 11.6 |
| mmHg | Lisdexamfetamine Dimesylate |
|---|---|
| Change From Baseline in Sitting Diastolic Blood Pressure (DBP) at Last On-treatment Assessment (LOTA) | 3.2 ± 9.05 |
| mmHg | Lisdexamfetamine Dimesylate |
|---|---|
| Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Last On-treatment Assessment (LOTA) | 3.4 ± 10.33 |
| kilogram(s) | Lisdexamfetamine Dimesylate |
|---|---|
| Change From Baseline in Body Weight at Last On-treatment Assessment (LOTA) | 2.1 ± 5.83 |
| centimeter(s) | Lisdexamfetamine Dimesylate |
|---|---|
| Change From Baseline in Height at Last On-treatment Assessment (LOTA) | 6.1 ± 4.9 |
BMI was calculated as (weight \[kilogram\] per height \[square meter\]).
| kilogram per square meter | Lisdexamfetamine Dimesylate |
|---|---|
| Change From Baseline in Body Mass Index (BMI) at Last On-treatment Assessment (LOTA) | -0.5 ± 1.72 |
| beats per minute | Lisdexamfetamine Dimesylate |
|---|---|
| Change From Baseline in Heart Rate at Last On-treatment Assessment (LOTA) | 7.1 ± 13.51 |
| milliseconds | Lisdexamfetamine Dimesylate |
|---|---|
| Change From Baseline in QT Interval at Last On-treatment Assessment (LOTA) | -10.3 ± 23.53 |
| milliseconds | Lisdexamfetamine Dimesylate |
|---|---|
| Change From Baseline in QT Interval Corrected Using Fridericia's Formula (QTcF) at Last On-treatment Assessment (LOTA) | -0.6 ± 15.24 |
The BPRS-C that was designed to provide a characterization of the child and adolescent psychopathology, was used to monitor participant's safety. The BPRS-C assessed 7 independent factors (3 items each), for a total of 21 items that represented behavioural disorders, depression, thinking disturbance, psychomotor excitation, withdrawal retardation, anxiety, and organicity. Each item was rated using a 7-point scale including 0 (not present), 1 (very mild), 2 (mild), 3 (moderate), 4 (moderately severe), 5 (severe), and 6 (extremely severe). Total score is the sum of each item score; range from 0 to 126. Higher score indicated worse psychology.
| scores on a scale | Lisdexamfetamine Dimesylate |
|---|---|
| Change From Baseline in Brief Psychiatric Rating Scale for Children (BPRSC) Total Scores at Last On-treatment Assessment (LOTA) | -10.3 ± 9.64 |
ADHD-RS-IV consisted of 18 items designed to reflect current symptomatology of ADHD based on Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition - Text Revision (DSM-IV-TR) criteria, completed by the Investigator. Each item was scored from a range of 0 (reflecting no symptoms) to 3 (reflecting severe symptoms) with total scores ranging from 0-54. The 18 items were grouped into 2 sub-scales: hyperactivity/impulsivity (even number items 2-18 with score range of 0 to 27) and inattention (odd number items 1-17 with score range of 0 to 27). Higher scores depicted worse symptoms.
| Scores on a scale | Lisdexamfetamine Dimesylate |
|---|---|
| Change From Baseline in the Attention-Deficit/Hyperactivity Disorder Rating Scale-IV (ADHD-RS-IV) Total Score at Last On-treatment Assessment (LOTA) | -25.8 ± 11.1 |
The Clinical Global Impressions (CGI) Scale permits a global evaluation of the participants' severity and improvement over time. This assessment will help guide the clinician on dosing adjustments. The CGI has been used extensively in clinical studies of ADHD. CGI-I was a 7-point scale ranging from 1 (very much improved) to 7 (very much worse), evaluated by the Investigator.
| participants | Lisdexamfetamine Dimesylate |
|---|---|
| Very much improved | 141 |
| Much improved | 92 |
| Minimally improved | 28 |
| No change | 20 |
| Minimally worse | 13 |
| Much worse | 5 |
| Very much worse | 0 |
The Clinical Global Impressions (CGI) Scale permits a global evaluation of the participants' severity and improvement over time. This assessment will help guide the clinician on dosing adjustments. The CGI has been used extensively in clinical studies of ADHD. CGI-S was a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill participants), evaluated by the Investigator.
| participants | Lisdexamfetamine Dimesylate |
|---|---|
| Normal, not all ill | 73 |
| Borderline mentally ill | 97 |
| Mildly ill | 67 |
| Moderately ill | 39 |
| Markedly ill | 17 |
| Severely ill | 4 |
| Among the most extremely ill participants | 2 |
Collected over Baseline up to 3 days after the last dose of study treatment (up to 2 years). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lisdexamfetamine Dimesylate | — | 28/314 (8.9%) | 250/314 (79.6%) |
| Event | Lisdexamfetamine Dimesylate |
|---|---|
| SyncopeNervous system disorders | 6/314 |
| AppendicitisInfections and infestations | 3/314 |
| PyelonephritisInfections and infestations | 2/314 |
| LymphadenitisBlood and lymphatic system disorders | 1/314 |
| ArrhythmiaCardiac disorders | 1/314 |
| Abdominal painGastrointestinal disorders | 1/314 |
| Dental cariesGastrointestinal disorders | 1/314 |
| DisbacteriosisGastrointestinal disorders | 1/314 |
| Condition aggravatedGeneral disorders | 1/314 |
| PyrexiaGeneral disorders | 1/314 |
| Event | Lisdexamfetamine Dimesylate |
|---|---|
| Decreased appetiteMetabolism and nutrition disorders | 170/314 |
| NasopharyngitisInfections and infestations | 73/314 |
| HeadacheNervous system disorders | 68/314 |
| Weight decreasedInvestigations | 63/314 |
| InsomniaPsychiatric disorders | 60/314 |
| Initial insomniaPsychiatric disorders | 38/314 |
| IrritabilityGeneral disorders | 36/314 |
| NauseaGastrointestinal disorders | 31/314 |
| PyrexiaGeneral disorders | 31/314 |
| Abdominal painGastrointestinal disorders | 29/314 |
| Age, Continuous(years) | Lisdexamfetamine Dimesylate |
|---|---|
| Mean | 11.4 ± 2.88 |
| Sex: Female, Male(Participants) | Lisdexamfetamine Dimesylate |
|---|---|
| Female | 64 |
| Male | 250 |
| Clinical Global Impressions - Severity of Illness (CGI-S) Rating(Participants) | Lisdexamfetamine Dimesylate |
|---|---|
| Normal, not all ill | 0 |
| Borderline mentally ill | 0 |
| Mildly ill | 1 |
| Moderately ill | 69 |
| Markedly ill | 152 |
| Severely ill | 81 |
| Among the most extremely ill participants | 11 |
| Body Weight(kilogram(s)) | Lisdexamfetamine Dimesylate |
|---|---|
| Mean | 46.13 ± 16.434 |
| Height(centimeters) | Lisdexamfetamine Dimesylate |
|---|---|
| Mean | 152.29 ± 16.633 |
| Body Mass Index (BMI)(kilogram per square meter) | Lisdexamfetamine Dimesylate |
|---|---|
| Mean | 19.22 ± 3.389 |
| Attention-Deficit/Hyperactivity Disorder Rating Scale-IV (ADHD-RS-IV): Total Score(scores on a scale) | Lisdexamfetamine Dimesylate |
|---|---|
| Mean | 41.1 ± 7.03 |
| ADHD-RS-IV: Inattention Subscale Score(scores on a scale) | Lisdexamfetamine Dimesylate |
|---|---|
| Mean | 22.1 ± 3.52 |
1 further baseline measures are reported on the registry.
Ran from Jul 2011 to primary completion in Sep 2014, 38 months.
Results were first posted in Aug 2015, 10 months after primary completion.
Of 62 phase 4 interventional studies under Attention Deficit Disorder with Hyperactivity, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 70. This study's 38 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lisdexamfetamine
Attention Deficit Disorder with Hyperactivity →